Evidence map›Paper›PMID 42797830›Full record

ArticleViruses2026

Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity.

Sarah-Kim Friedrich-Becker, Michael Bergerhausen, Arshia Berry, Hilal Bhat, Fanghui Li, Rosa Schmitz, Lisa Holnsteiner, Dethardt Müller, Haifeng Xu, Philipp A Lang and 2 more

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah-Kim Friedrich-BeckerAbalos Therapeutics GmbH, 40225 Düsseldorf, Germany.
Michael BergerhausenAbalos Therapeutics GmbH, 40225 Düsseldorf, Germany.ORCID 0009-0003-2900-6983
Arshia BerryAbalos Therapeutics GmbH, 40225 Düsseldorf, Germany.
Hilal BhatInstitute of Immunology, University Hospital of Essen, 45147 Essen, Germany.
Fanghui LiInstitute of Immunology, University Hospital of Essen, 45147 Essen, Germany.
Rosa SchmitzInstitute of Immunology, University Hospital of Essen, 45147 Essen, Germany.ORCID 0000-0002-3578-7179
Lisa HolnsteinerInstitute of Immunology, University Hospital of Essen, 45147 Essen, Germany.ORCID 0009-0003-5339-6942
Dethardt MüllerAbalos Therapeutics GmbH, 40225 Düsseldorf, Germany.
Haifeng XuDepartment of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
Philipp A LangDepartment of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
Karl Sebastian LangInstitute of Immunology, University Hospital of Essen, 45147 Essen, Germany.
Jörg VollmerAbalos Therapeutics GmbH, 40225 Düsseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of effective viroimmunotherapies for cancer relies on the ability of replicating viruses to infect the entire tumor tissue and induce comprehensive inflammation within the tumor microenvironment (TME). In this study, we investigate the impact of mutations in the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) on tumor cell infectivity, replication, and the immune response. Specifically, we focus on two key positions in GP1 (181 and 185) that significantly enhance tumor cell infectivity and improve CD8

Indexed as

Lymphocytic choriomeningitis virusMutationNeoplasmsViral TropismAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceMice, Inbred C57BLOncolytic VirotherapyTumor MicroenvironmentVirus Replicationadaptive immunitycancercold tumorshot tumorsinnate immunityLCMVtumor microenvironmentviroimmunotherapy

Identifiers

PMID42797830
PMCPMC13611857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.